Villejuif

• Study of INBRX-109 in Patients with Advanced Solid Tumors, Including Sarcomas. Recruiting
  2023-508139-29-00 7 2024-06-26 Advanced or metastatic solid tumors
• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 5 2024-06-24 Advanced Biliary Cancer (ABC)
• A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or … Recruiting
  2023-504514-29-00 1 2024-06-18 Gastroesophageal Junction (GEJ) Adenocarcinoma
• A Phase 1 study of JNJ-87704916, a tumor-targeting virus, injected into tumor for advanced cancer Recruiting
  2023-506495-27-00 1 2024-06-18 Advanced solid tumors
• Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding … Recruiting
  2023-503606-36-00 9 2024-06-17 Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ o
• Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - RED Randomized phase … Recruiting
  2023-503886-44-00 5 2024-06-10 Patients with a histological diagnosis of p53abn HREC, treated with cu
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting
  2023-504251-27-00 7 2024-05-27 Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
• A study of ASP3082 in adults with advanced solid tumors Recruiting
  2022-501590-39-00 1 2024-05-22 Solid Tumor
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 Advanced or metastatic solid tumors including hormone receptor positiv
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga … Recruiting
  2023-504600-28-00 10 2024-05-09 Metastatic Hepatocellular Carcinoma (HCC)
• Basket study for oligo-metastatic breast cancer - ANISE Recruiting
  2023-505039-11-00 4 2024-05-02 breast cancer, HER2-positive, oligometastatic disease
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 Cholangiocarcinoma (LTT, 26.0)
• Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas … Recruiting
  2023-506753-38-00 4 2024-04-16 metastatic gastric adenocarcinoma
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors Recruiting
  2023-505358-16-00 1 2024-04-11 Advanced Solid Tumors
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting
  2023-506759-51-00 7 2024-03-29 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenoc … Recruiting
  2023-506885-30-00 5 2024-03-26 Adult patients with intermediate low or mid rectal adenocarcinoma to b
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer

Showing 361–384 of 961 trials